Tag Archive for: Amgen

The companies have filed their own suit against the Federal Trade Commission, claiming the FTC’s attempt to legally block their $28 billion merger is unconstitutional.

AbbVie’s Humira will now face lower-price competition from four new biosimilars: Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.

Six U.S. states are joining the Federal Trade Commission’s lawsuit seeking to block Amgen’s $27.8 billion buyout of rare disease biotech Horizon Therapeutics, Reuters reported on Thursday.

Following a May 2023 settlement with Amgen, J&J has also signed an agreement with Teva and Alvotech, allowing their Stelara biosimilar to enter the U.S. no later than February 21, 2025.

The entry of biosimilars promotes healthy market competition. It can reduce the prices of branded biologic medicines, according to a new study from the University of Southern California’s Leonard D. Schaeffer Center for Health Policy & Economics.

The Federal Trade Commission’s lawsuit takes an unusual strategy, according to legal experts, raising concerns and uncertainties in the biopharma industry.

Johnson & Johnson’s legal settlement with Amgen to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting.

Coherus BioSciences Inc. said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.

Yesterday’s patent settlement comes as the biopharma industry is faced with one of its steepest patent cliffs. By 2030, nearly 200 medicines will go off-patent, of which 69 are blockbuster drugs.

The U.S. Supreme Court unanimously ruled Amgen’s cholesterol drug Repatha patents invalid, ending a protracted legal battle with competitors Sanofi and Regeneron.